Literature DB >> 23715325

Putting a halt on PRC2 in pediatric glioblastoma.

Philipp Voigt1, Danny Reinberg.   

Abstract

Two new studies show that the known histone H3 alteration p.Lys27Met in pediatric glioma leads to globally diminished trimethylation at histone H3 lysine 27. The mutant histone H3 acts as a selective inhibitor of the PRC2 chromatin-modifying complex by binding and presumably sequestering it, shedding light on how this variant may contribute to the etiology of these highly malignant brain tumors.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23715325     DOI： 10.1038/ng.2647

Source DB:  PubMed          Journal:  Nat Genet        ISSN： 1061-4036            Impact factor:   38.330


  14 in total

1.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.

Authors:  Christopher J Sneeringer; Margaret Porter Scott; Kevin W Kuntz; Sarah K Knutson; Roy M Pollock; Victoria M Richon; Robert A Copeland
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

2.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.

Authors:  Jeremy Schwartzentruber; Andrey Korshunov; Xiao-Yang Liu; David T W Jones; Elke Pfaff; Karine Jacob; Dominik Sturm; Adam M Fontebasso; Dong-Anh Khuong Quang; Martje Tönjes; Volker Hovestadt; Steffen Albrecht; Marcel Kool; Andre Nantel; Carolin Konermann; Anders Lindroth; Natalie Jäger; Tobias Rausch; Marina Ryzhova; Jan O Korbel; Thomas Hielscher; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Martin Ebinger; Martin U Schuhmann; Wolfram Scheurlen; Arnulf Pekrun; Michael C Frühwald; Wolfgang Roggendorf; Christoph Kramm; Matthias Dürken; Jeffrey Atkinson; Pierre Lepage; Alexandre Montpetit; Magdalena Zakrzewska; Krzystof Zakrzewski; Pawel P Liberski; Zhifeng Dong; Peter Siegel; Andreas E Kulozik; Marc Zapatka; Abhijit Guha; David Malkin; Jörg Felsberg; Guido Reifenberger; Andreas von Deimling; Koichi Ichimura; V Peter Collins; Hendrik Witt; Till Milde; Olaf Witt; Cindy Zhang; Pedro Castelo-Branco; Peter Lichter; Damien Faury; Uri Tabori; Christoph Plass; Jacek Majewski; Stefan M Pfister; Nada Jabado
Journal:  Nature       Date:  2012-01-29       Impact factor: 49.962

3.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

Authors:  Michael T McCabe; Heidi M Ott; Gopinath Ganji; Susan Korenchuk; Christine Thompson; Glenn S Van Aller; Yan Liu; Alan P Graves; Anthony Della Pietra; Elsie Diaz; Louis V LaFrance; Mark Mellinger; Celine Duquenne; Xinrong Tian; Ryan G Kruger; Charles F McHugh; Martin Brandt; William H Miller; Dashyant Dhanak; Sharad K Verma; Peter J Tummino; Caretha L Creasy
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

4.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.

Authors:  Sarah K Knutson; Tim J Wigle; Natalie M Warholic; Christopher J Sneeringer; Christina J Allain; Christine R Klaus; Joelle D Sacks; Alejandra Raimondi; Christina R Majer; Jeffrey Song; Margaret Porter Scott; Lei Jin; Jesse J Smith; Edward J Olhava; Richard Chesworth; Mikel P Moyer; Victoria M Richon; Robert A Copeland; Heike Keilhack; Roy M Pollock; Kevin W Kuntz
Journal:  Nat Chem Biol       Date:  2012-09-30       Impact factor: 15.040

5.  H3F3A K27M mutation in pediatric CNS tumors: a marker for diffuse high-grade astrocytomas.

Authors:  Gerrit H Gielen; Marco Gessi; Jennifer Hammes; Christof M Kramm; Andreas Waha; Torsten Pietsch
Journal:  Am J Clin Pathol       Date:  2013-03       Impact factor: 2.493

6.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma.

Authors:  Dominik Sturm; Hendrik Witt; Volker Hovestadt; Dong-Anh Khuong-Quang; David T W Jones; Carolin Konermann; Elke Pfaff; Martje Tönjes; Martin Sill; Sebastian Bender; Marcel Kool; Marc Zapatka; Natalia Becker; Manuela Zucknick; Thomas Hielscher; Xiao-Yang Liu; Adam M Fontebasso; Marina Ryzhova; Steffen Albrecht; Karine Jacob; Marietta Wolter; Martin Ebinger; Martin U Schuhmann; Timothy van Meter; Michael C Frühwald; Holger Hauch; Arnulf Pekrun; Bernhard Radlwimmer; Tim Niehues; Gregor von Komorowski; Matthias Dürken; Andreas E Kulozik; Jenny Madden; Andrew Donson; Nicholas K Foreman; Rachid Drissi; Maryam Fouladi; Wolfram Scheurlen; Andreas von Deimling; Camelia Monoranu; Wolfgang Roggendorf; Christel Herold-Mende; Andreas Unterberg; Christof M Kramm; Jörg Felsberg; Christian Hartmann; Benedikt Wiestler; Wolfgang Wick; Till Milde; Olaf Witt; Anders M Lindroth; Jeremy Schwartzentruber; Damien Faury; Adam Fleming; Magdalena Zakrzewska; Pawel P Liberski; Krzysztof Zakrzewski; Peter Hauser; Miklos Garami; Almos Klekner; Laszlo Bognar; Sorana Morrissy; Florence Cavalli; Michael D Taylor; Peter van Sluis; Jan Koster; Rogier Versteeg; Richard Volckmann; Tom Mikkelsen; Kenneth Aldape; Guido Reifenberger; V Peter Collins; Jacek Majewski; Andrey Korshunov; Peter Lichter; Christoph Plass; Nada Jabado; Stefan M Pfister
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

7.  EZH2 is essential for glioblastoma cancer stem cell maintenance.

Authors:  Mario-Luca Suvà; Nicolò Riggi; Michalina Janiszewska; Ivan Radovanovic; Paolo Provero; Jean-Christophe Stehle; Karine Baumer; Marie-Aude Le Bitoux; Denis Marino; Luisa Cironi; Victor E Marquez; Virginie Clément; Ivan Stamenkovic
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

Review 8.  Occupying chromatin: Polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put.

Authors:  Jeffrey A Simon; Robert E Kingston
Journal:  Mol Cell       Date:  2013-03-07       Impact factor: 17.970

Review 9.  The Polycomb complex PRC2 and its mark in life.

Authors:  Raphaël Margueron; Danny Reinberg
Journal:  Nature       Date:  2011-01-20       Impact factor: 49.962

Review 10.  The 2007 WHO classification of tumours of the central nervous system.

Authors:  David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues
Journal:  Acta Neuropathol       Date:  2007-07-06       Impact factor: 17.088
View more
  5 in total

Review 1.  Molecular insights into pediatric brain tumors have the potential to transform therapy.

Authors:  Amar Gajjar; Stefan M Pfister; Michael D Taylor; Richard J Gilbertson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

2.  Polycomb Repressive Complex 1 Generates Discrete Compacted Domains that Change during Differentiation.

Authors:  Sharmistha Kundu; Fei Ji; Hongjae Sunwoo; Gaurav Jain; Jeannie T Lee; Ruslan I Sadreyev; Job Dekker; Robert E Kingston
Journal:  Mol Cell       Date:  2017-02-02       Impact factor: 17.970

3.  Simultaneous disruption of PRC2 and enhancer function underlies histone H3.3-K27M oncogenic activity in human hindbrain neural stem cells.

Authors:  Gerard L Brien; Raul Bardini Bressan; Craig Monger; Dáire Gannon; Eimear Lagan; Anthony M Doherty; Evan Healy; Hannah Neikes; Darren J Fitzpatrick; Orla Deevy; Vivien Grant; Maria-Angeles Marqués-Torrejón; Neza Alfazema; Steven M Pollard; Adrian P Bracken
Journal:  Nat Genet       Date:  2021-07-22       Impact factor: 38.330

Review 4.  Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications.

Authors:  Wei Wang; Jiang-Jiang Qin; Sukesh Voruganti; Subhasree Nag; Jianwei Zhou; Ruiwen Zhang
Journal:  Med Res Rev       Date:  2015-07-30       Impact factor: 12.944

5.  Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric glioma.

Authors:  James M Stafford; Chul-Hwan Lee; Philipp Voigt; Nicolas Descostes; Ricardo Saldaña-Meyer; Jia-Ray Yu; Gary Leroy; Ozgur Oksuz; Jessica R Chapman; Fernando Suarez; Aram S Modrek; N Sumru Bayin; Dimitris G Placantonakis; Matthias A Karajannis; Matija Snuderl; Beatrix Ueberheide; Danny Reinberg
Journal:  Sci Adv       Date:  2018-10-31       Impact factor: 14.136
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.